Sugi Predict

Sugi Predict / Compounds / SCHEMBL5123072

SCHEMBL5123072

SCHEMBL5123072

N#Cc1cnc2[nH]ncc2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ HPGDS O60760 2/20 0.40
▸ HTT P42858 1/20 0.40
▸ RIPK1 Q13546 1/20 0.39
▸ NAMPT P43490 1/20 0.37
▸ BRAF P15056 5/20 0.36
▸ METAP2 P50579 1/20 0.35
▸ EGFR P00533 1/20 0.34
▸ PRKDC P78527 1/20 0.34
▸ DDR1 Q08345 1/20 0.34
▸ RET P07949 1/20 0.34
▸ PI4KA P42356 1/20 0.34
▸ XDH P47989 1/20 0.34
▸ LRRK2 Q5S007 1/20 0.34
▸ PI4K2B Q8TCG2 1/20 0.34
▸ PI4K2A Q9BTU6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30726289 1.00 KDM4E (0.41) KDM4EALDH1A1LMNAGAAL3MBTL1
SCHEMBL502852 0.80 PARP1 (0.37) BRAFEGFRPRKDCRETPI4KA
SCHEMBL29626963 0.74 HPGDS (0.36) KDM4EALDH1A1LMNAGAAL3MBTL1
SCHEMBL503744 0.74 BRAF (0.39) BRAFRETPI4KAXDHLRRK2
SCHEMBL298150 0.73 RIPK1 (0.69) HPGDSRIPK1RETLRRK2
SCHEMBL25952937 0.73 BRAF (0.40) BRAFRETPI4KAXDHLRRK2
SCHEMBL1586122 0.73 CYP2C19 (0.42) ALDH1A1BRAFRETPI4KAXDH
SCHEMBL28227220 0.72 HPGDS (0.37) KDM4EALDH1A1LMNAGAAL3MBTL1
SCHEMBL20125054 0.72 BRD4 (0.44) KDM4EALDH1A1LMNAGAAL3MBTL1
SCHEMBL19250635 0.71 DYRK1A (0.53) KDM4EALDH1A1LMNAGAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3313840-A1 HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS Bristol-Myers Squibb Company (US) 2018-05-02 — — EP claimed
WO-2016210034-A1 HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-12-29 — — WO claimed
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
US-20250376443-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-12-11 — — US disclosed
US-20250368604-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-12-04 — — US disclosed
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 — — US disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 — — EP disclosed
WO-2025151602-A1 HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 BRISTOL-MYERS SQUIBB COMPANY (US) 2025-07-17 — — WO disclosed
WO-2025151728-A1 LIGAND DIRECTED DEGRADER OF IRAK4 BRISTOL-MYERS SQUIBB COMPANY (US) 2025-07-17 — — WO disclosed
US-12331068-B2 Compositions and methods for inhibiting CD73 PELOTON THERAPEUTICS, INC. (US) 2025-06-17 — — US disclosed
WO-2016210034-A1 HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-12-29 — — WO disclosed
EP-3089973-A1 HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS Bristol-Myers Squibb Company (US) 2016-11-09 — — EP disclosed
US-9169252-B2 Heteroaryl substituted nicotinamide compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2015-10-27 — — US disclosed
US-20150191464-A1 HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2015-07-09 — — US disclosed
WO-2015103453-A1 HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2015-07-09 — — WO disclosed
CN-103980272-A Method for synthesis of 5-cyano-1H-pyrazolo[3,4-b]pyridine HAIMEN RUIYI MEDICAL TECHNOLOGY CO LTD 2014-08-13 — — CN disclosed
CN-103980272-A Method for synthesis of 5-cyano-1H-pyrazolo[3,4-b]pyridine HAIMEN RUIYI MEDICAL TECHNOLOGY CO LTD 2014-08-13 — — CN disclosed
US-7459451-B2 e.g. 1-Ethyl-4-(5-methyl-3-pyridyl)-6-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid; phosphodiesterase (PDE)-IV inhibitor or tumor necrosis factor (TNF)- alpha antagonist; autoimmune diseases, antidepressant, anxiolytic agent; polychondritis, scleroderma, fibrosis, arthritis, Alzheimer's disease ASTELLAS PHARMA INC. (JP) 2008-12-02 — — US disclosed
US-20060004003-A1 Pyrazolopyridine derivatives ASTELLAS PHARMA INC. (JP) 2006-01-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM4E 190/4885ALDH1A1 2776/4885LMNA 1656/4885
US-20250368604-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 KDM4E 4128/4885ALDH1A1 4701/4885LMNA 3465/4885
US-20250376443-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 KDM4E 4206/4885ALDH1A1 4718/4885LMNA 3016/4885
US-12331068-B2 Compositions and methods for inhibiting CD73 ENTPD5, NT5E, ENTPD1 KDM4E 1503/4885ALDH1A1 868/4885LMNA 773/4885
US-20060004003-A1 Pyrazolopyridine derivatives PDE4A, PDE3B, PDE5A KDM4E 2228/4885ALDH1A1 774/4885LMNA 3462/4885
US-20150191464-A1 HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS IRAK4, IRAK3, IRAK2 KDM4E 459/4885ALDH1A1 1647/4885LMNA 3020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.